[1]
|
Charo, L.M., et al. (2021) Clinical Implications of Plasma Circulating Tumor DNA in Gynecologic Cancer Patients. Mo-lecular Oncology, 15, 67-79. https://doi.org/10.1002/1878-0261.12791
|
[2]
|
Yang, F., Tang, J., Zhao, Z.H., Zhao, C.L. and Xiang, Y.C. (2021) Circulating Tumor DNA: A Noninvasive Biomarker for Tracking Ovarian Cancer. Repro-ductive Biology and Endocrinology, 19, Article No. 178.
https://doi.org/10.1186/s12958-021-00860-8
|
[3]
|
Pessoa, L.S., Heringer, M. and Ferrer, V.P. (2020) ctDNA as a Cancer Biomarker: A Broad Overview. Critical Reviews in Oncology/Hematology, 155, Article ID: 103109. https://doi.org/10.1016/j.critrevonc.2020.103109
|
[4]
|
Campos-Carrillo, A., et al. (2020) Circulating Tumor DNA as an Early Cancer Detection Tool. Pharmacology & Therapeutics, 207, Article ID: 107458. https://doi.org/10.1016/j.pharmthera.2019.107458
|
[5]
|
Stroun, M., et al. (1989) Neoplastic Characteristics of the DNA Found in the Plasma of Cancer Patients. Oncology, 46, 318-322. https://doi.org/10.1159/000226740
|
[6]
|
Mouliere, F., et al. (2011) High Fragmentation Characterizes Tu-mour-Derived Circulating DNA. PLOS ONE, 6, e23418. https://doi.org/10.1371/journal.pone.0023418
|
[7]
|
Underhill, H.R., et al. (2016) Fragment Length of Circulating Tumor DNA. PLOS Genetics, 12, e1006162.
https://doi.org/10.1371/journal.pgen.1006162
|
[8]
|
Keller, L., Belloum, Y., Wikman, H. and Pantel, K. (2021) Clin-ical Relevance of Blood-Based ctDNA Analysis: Mutation Detection and Beyond. British Journal of Cancer, 124, 345-358. https://doi.org/10.1038/s41416-020-01047-5
|
[9]
|
Burrell, R.A., McGranahan, N., Bartek, J. and Swan-ton, C. (2013) The Causes and Consequences of Genetic Heterogeneity in Cancer Evolution. Nature, 501, 338-345. https://doi.org/10.1038/nature12625
|
[10]
|
Sokoll, L., et al. (2008) Circulating Mutant DNA to Assess Tumor Dy-namics. Nature Medicine, 14, 985-990.
https://doi.org/10.1038/nm.1789
|
[11]
|
Weber, S., et al. (2020) Technical Evaluation of Commercial Mutation Anal-ysis Platforms and Reference Materials for Liquid Biopsy Profiling. Cancers, 12, Article 1588. https://doi.org/10.3390/cancers12061588
|
[12]
|
Romero, A., et al. (2021) Comprehensive Cross-Platform Compari-son of Methods for Non-Invasive EGFR Mutation Testing: Results of the RING Observational Trial. Molecular Oncol-ogy, 15, 43-56.
https://doi.org/10.1002/1878-0261.12832
|
[13]
|
Jie, X., et al. (2022) Mutation Analysis of Circulating Tumor DNA and Paired Ascites and Tumor Tissues in Ovarian Cancer. Experimental and Therapeutic Medicine, 24, Article No. 542. https://doi.org/10.3892/etm.2022.11479
|
[14]
|
Raymond, V.M., Higashi, L., Marino, E. and Lang, K. (2021) Evalua-tion of the ctDNA LUNAR-2 Test In an Average Patient Screening Episode (ECLIPSE). Journal of Clinical Oncology, 39, TPS142-TPS142.
https://doi.org/10.1200/JCO.2021.39.3_suppl.TPS142
|
[15]
|
Rolfo, C., et al. (2020) Challenges and Opportunities of cfDNA Analysis Implementation in Clinical Practice: Perspective of the International Society of Liquid Biopsy (ISLB). Critical Reviews in Oncology/Hematology, 151, Article ID: 102978. https://doi.org/10.1016/j.critrevonc.2020.103058
|
[16]
|
Bettegowda, C., et al. (2014) Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Science Translational Medicine, 6, 224ra24.
|
[17]
|
Maritschnegg, E., et al. (2015) Lavage of the Uterine Cavity for Molecular Detection of Müllerian Duct Carcinomas: A Proof-of-Concept Study. Journal of Clinical Oncology, 33, 4293-4300. https://doi.org/10.1200/JCO.2015.61.3083
|
[18]
|
Zhou, J., et al. (2015) Urinary microRNA-30a-5p Is a Potential Biomarker for Ovarian Serous Adenocarcinoma. Oncology Reports, 33, 2915-2923. https://doi.org/10.3892/or.2015.3937
|
[19]
|
Lukasiewicz, M., et al. (2021) Diagnostic Accuracy of Liq-uid Biopsy in Endometrial Cancer. Cancers, 13, Article 5731. https://doi.org/10.3390/cancers13225731
|
[20]
|
Bolivar, A.M., et al. (2019) Targeted Next-Generation Sequencing of Endometrial Cancer and Matched Circulating Tumor DNA: Identification of Plasma-Based, Tumor-Associated Muta-tions in Early Stage Patients. Modern Pathology, 32, 405-414. https://doi.org/10.1038/s41379-018-0158-8
|
[21]
|
Veyer, D., et al. (2020) HPV Circulating Tumoral DNA Quanti-fication by Droplet-Based Digital PCR: A Promising Predictive and Prognostic Biomarker for HPV-Associated Oropha-ryngeal Cancers. International Journal of Cancer, 147, 1222-1227. https://doi.org/10.1002/ijc.32804
|
[22]
|
Jeannot, E., et al. (2016) Circulating Human Papillomavirus DNA Detected Using Droplet Digital PCR in the Serum of Patients Diagnosed with Early Stage Human Papillomavirus-Associated Invasive Carcinoma. The Journal of Pathology: Clinical Research, 2, 201-209. https://doi.org/10.1002/cjp2.47
|
[23]
|
Damerla, R.R., et al. (2019) Detection of Early Human Papillomavirus-Associated Cancers by Liquid Biopsy. JCO Precision Oncology, 3, 1-11. https://doi.org/10.1200/PO.18.00276
|
[24]
|
Kang, Z., Stevanović, S., Hinrichs, C.S. and Cao, L. (2017) Circulating Cell-Free DNA for Metastatic Cervical Cancer Detection, Genotyping, and Monitoring. Clinical Cancer Research, 23, 6856-6862.
https://doi.org/10.1158/1078-0432.CCR-17-1553
|
[25]
|
Marsavela, G., et al. (2022) Detection of Clinical Progres-sion through Plasma ctDNA in Metastatic Melanoma Patients: A Comparison to Radiological Progression. British Jour-nal of Cancer, 126, 401-408.
https://doi.org/10.1038/s41416-021-01507-6
|
[26]
|
Reece, M., et al. (2019) The Use of Circulating Tumor DNA to Monitor and Predict Response to Treatment in Colorectal Cancer. Frontiers in Genetics, 10, Article 482516. https://doi.org/10.3389/fgene.2019.01118
|
[27]
|
Yi, X., et al. (2017) The Feasibility of Using Mutation Detection in ctDNA to Assess Tumor Dynamics. International Journal of Cancer, 140, 2642-2647. https://doi.org/10.1002/ijc.30620
|
[28]
|
Kidess, E., et al. (2015) Mutation Profiling of Tumor DNA from Plasma and Tumor Tissue of Colorectal Cancer Patients with A novel, High-Sensitivity Multiplexed Mutation Detection Platform. Oncotarget, 6, 2549-2561.
https://doi.org/10.18632/oncotarget.3041
|
[29]
|
Zhu, J.W., et al. (2023) Evaluating the Utility of ctDNA in Detecting Residual Cancer and Predicting Recurrence in Patients with Serous Ovarian Cancer. International Journal of Molecular Sciences, 24, Article 14388.
https://doi.org/10.3390/ijms241814388
|
[30]
|
Hou, J.Y., et al. (2022) Circulating Tumor DNA Monitoring for Early Recurrence Detection in Epithelial Ovarian Cancer. Gynecologic Oncology, 167, 334-341. https://doi.org/10.1016/j.ygyno.2022.09.004
|
[31]
|
Campitelli, M., et al. (2012) Human Papillomavirus Mutational Insertion: Specific Marker of Circulating Tumor DNA in Cervical Cancer Patients. PLOS ONE, 7, e43393. https://doi.org/10.1371/journal.pone.0043393
|
[32]
|
Gadducci, A., Tana, R., Cosio, S. and Genazzani, A.R. (2008) The Serum Assay of Tumour Markers in the Prognostic Evaluation, Treatment Monitoring and Follow-Up of Patients with Cervical Cancer: A Review of the Literature. Critical Reviews in Oncology/Hematology, 66, 10-20. https://doi.org/10.1016/j.critrevonc.2007.09.002
|
[33]
|
Sharbatoghli, M., et al. (2020) Prediction of the Treatment Response in Ovarian Cancer: A ctDNA Approach. Journal of Ovarian Research, 13, Article No. 124. https://doi.org/10.1186/s13048-020-00729-1
|